Navigation Links
Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.
Date:1/27/2011

NATICK, Mass., Jan. 27, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI clinical trial.  BLOCk-CTI is a prospective, randomized trial evaluating the safety and effectiveness of the Blazer Open-Irrigated Catheter in patients with sustained or recurrent Type 1 atrial flutter.  The trial plans to enroll up to 240 patients at 22 sites in the U.S.

Atrial flutter is an arrhythmia associated with the right atrium of the heart that affects nearly 1 million people in the U.S.  Patients with Type 1 atrial flutter may exhibit symptoms including palpitations, shortness of breath, fatigue, lightheadedness and fainting.  Catheter ablation has become a first-line treatment approach for patients with recurrent Type 1 atrial flutter, demonstrating more successful short- and long-term outcomes compared to anti-arrhythmic drugs.

"The Blazer Open-Irrigated Catheter combines a new technique for irrigated ablation with the reliability of the proven Blazer platform," said Emile Daoud, M.D., Section Chief, Cardiac Electrophysiology, Ross Heart Hospital at the Ohio State University Medical Center in Columbus, who performed the first U.S. procedure.  "The open-irrigated catheter performed well with excellent maneuverability, torque and catheter stability."

The Blazer Open-Irrigated Catheter integrates Total Tip Cooling Technology with the high-performance Blazer® Catheter Platform.  Total Tip Cooling Technology is intended to offer consistent cooling of the entire ablation tip electrode throughout radiofrequency energy delivery.

"The first U.S. use of the Blazer Open-Irrigated Catheter highlights our continued focus on providing the most advanced ablation technologies to electrophysiologists," said Hank Kucheman, Executive
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
2. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
3. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
4. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
5. Boston Scientific to Acquire Atritech
6. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
7. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
8. Boston Scientific Completes Acquisition of Sadra Medical
9. Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
10. Boston Scientific Completes Sale of Neurovascular Business
11. Boston Scientific to Present at 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
(Date:3/2/2015)... CA (PRWEB) March 02, 2015 Gummy ... gum reshaping procedures. Gum reshaping can involve one or several ... to regenerate lost gum tissue for a more even gum ... dark gum line treatment that can permanently lighten discolored ... total smile approach, which involves a personalized treatment plan to ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service offers ... Platinum Resistance Thermometers (SSPRTs) and industrial Resistance Temperature ... . . . guaranteed. Their metrology ... 200706-0), ISO 9001 and 17025 Certified and provides ... to 500°C, both ITS-90 and Callendar-van Dusen calibrations ...
(Date:3/2/2015)... 2015 Over the last five years ... vendors seeking to expand their geographic presence and achieve ... to reach $6.2 billion by 2019 at CAGR of ... the U.S. and Canada and a major part of ... regions such as Asia-Pacific including China and India, Latin ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual awareness ... people across the country to unite, raise awareness, ... their best lives. MS Awareness Week is a special week ... the Society’s vision of a world free of MS. ... the central nervous system, interrupts the flow of information within ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased ... Health Plans: 2015 , the all-new 12th edition of ... plan market, with enrollment data and contact information for ... Available as a printed book containing the full directory ... tables and charts, as well as an electronic version, ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2
... users were informed of their odds for cardiovascular ... Letting patients know how cholesterol boosts their heart ... researchers report. , Researchers at McGill University in ... the study) with cholesterol problems who were instructed ...
... In the very first trial of its kind in ... find out if water softeners can help in the ... by clinicians at The University of Nottingham has received ... National Institute for Health Research (NIHR) Health Technology Assessment ...
... , McGill University researchers have uncovered the crucial role ... onset of breast cancer. The research, led by Dr. William ... Institute for Cancer Research in Scotland was published the ... Academy of Sciences (PNAS). The study,s first author is Dr. ...
... Net Income Increases 22% and Royalty Income Increases 29% ... ... Unilens Vision Inc. (OTC,Bulletin Board: UVICF) (TSX Venture Exchange: UVI), ... operating results for the first quarter of FY2008., Net sales, ...
... Switzerland, November 29 Biolytix AG,( http://www.biolytix.ch ... UK Ltd ( http://www.affymetrix.com ) and offers ... R&D community under conditions,compliant with a stringent ... the leading CRO,s for molecular biological analysis ...
... 29 BlueCross BlueShield of South,Carolina and ... have,streamlined access to international dental services through ... Healthcare Inc., Earlier this year, Companion ... members access to medical and surgical treatment,at ...
Cached Medicine News:Health News:Knowing Heart Risk Keeps Patients on Cholesterol Drugs 2Health News:Eczema sufferers test out benefits of water softeners 2Health News:Eczema sufferers test out benefits of water softeners 3Health News:McGill researchers link enzyme to breast cancer malignancy 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4Health News:Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix' GeneChip(R) Technology 2Health News:S.C. BlueCross, BlueChoice HealthPlan Expand Global Offerings to Include Dental Services 2
West lacrimal cannula blunt tip with side port....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Shahinian lacrimal cannula, bullet shaped tip, 0.3 mm side opening, straight....
Medicine Products: